Cancer BiologybioRxivPreprint
PDK1 and YAP1/TEAD signaling drive acquired KRAS inhibitor resistance in KRAS-mutant non-small cell lung cancer.
Amrita Barua, Samrat T. Kundu, Sofia Garza…·Don Lynn Gibbons
This study identifies PDK1 and YAP1/TEAD signaling as drivers of acquired resistance to KRAS inhibitors in NSCLC and suggests their co-targeting as a potential therapeutic strategy.
DOI 10.64898/2025.12.22.696060